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The assessment of parent- and child-reported outcomes 
(PCROs) is gaining increasing importance in the manage-
ment of children with rheumatic disorders. Parents and chil-
dren (when mature enough to understand the clinical and 
therapeutic issues related to their disease) are asked with 
increasing frequency to actively participate in shared deci-
sion-making and the integration of their perspective in clini-
cal assessment may facilitate concordance with physician’s 
choices and improve adherence to treatment. In addition, 
the use of PCROs may help the physician to identify with 
greater accuracy the salient issues for each patient and to 
focus the attention on the relevant matters. It is now agreed 
that the inclusion of PCROs in clinical practice may lead to 
improve the quality of care. In keeping with these principles, 
regulatory bodies such as the Food and Drug Administration 
and the European Medicine Agency recommend the use of 
PCROs in paediatric clinical trials.
A number of tools for the assessment of PCROs in pae-
diatric rheumatic diseases are available, including visual 
analogue scales for rating of child’s overall well-being and 
intensity of pain, and questionnaires for the estimation of 
functional ability and health-related quality of life (HRQL). 
These clinical measures have been included in several obser-
vational studies, therapeutic trials, and long-term outcome 
surveys and some of them are included in standardized core 
sets of outcome measures, disease activity state definitions, 
or composite disease activity scores for juvenile idiopathic 
arthritis (JIA). However, in spite of their popularity and 
large-scale adoption, most of the instruments used to assess 
PCROs have remained fundamentally research tools and are 
not routinely administered in most paediatric rheumatology 
centres. One of the reasons that may explain why these eval-
uations are uncommonly performed in daily clinical care is 
the length and complexity of some questionnaires, particu-
larly those used for the assessment of physical function and 
HRQL. There is the concern that their regular administration 
may interfere with routine clinical activity, with consequent 
increased costs and time.
On the other hand, the heterogeneous and multidimen-
sional nature of JIA implies that numerous disease domains 
should be evaluated simultaneously to appraise the full 
impact of the illness. In this respect, there are several PCROs 
not addressed by conventional instruments, such as morning 
stiffness and overall level of disease activity, disease status 
and course, proxy- or self-assessment of joint involvement 
and extra-articular symptoms, side effects of medications, 
therapeutic compliance, and satisfaction with the outcome 
of the illness, which may provide important insights into the 
influence of the disease and its treatment on child’s health.
Information related to PCROs is usually obtained from 
parents and children in form of interview at the time of the 
visit and is recorded in clinical charts or computer-based 
records as written notes. However, collecting this data in a 
standardized form would provide a physician with a thor-
ough and systematic overview of the patient status to be 
scanned quickly at the beginning of the visit. Pursuing this 
objective through the administration of multiple lengthy 
questionnaires is clearly not feasible in a busy clinic. Assess-
ment tools for use in routine clinical care must be at the same 
time comprehensive and practical.
These considerations have provided the rationale for the 
development in 2011 of the Juvenile Arthritis Multidimen-
sional Assessment Report (JAMAR), a multidimensional 
questionnaire for the assessment of patients with JIA in 
standard clinical care that incorporates all main PCROs. 
The JAMAR addresses all domains included in the WHO 
International Classification of Functioning and Health. The 
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JAMAR is proposed for use as both proxy-report and patient 
self-report, with the suggested age range of 7–18 years 
for use as self-report. The questionnaire format has been 
found very user-friendly, easy to understand, and readily 
responded to by parents and children. It is quick, taking less 
than 15 minutes to complete and can be scanned by a health 
professional for a clinical overview in a few seconds. Scor-
ing of its components can be performed in less than 5 min.
The JAMAR has been selected for the assessment of 
PCROs in a multinational study aimed to investigate the 
EPidemiology, treatment and Outcome of Childhood Arthri-
tis throughout the world (EPOCA Study). The study is pri-
marily aimed to obtain information on the frequency of JIA 
categories in different geographic areas, the therapeutic 
interventions made by paediatric rheumatologists practicing 
in diverse countries or continents, and the current disease 
and health status of children with JIA followed worldwide. 
Additional aims are to investigate the availability of biologic 
medications in developing countries and to foster the regu-
lar quantitative clinical assessment of children with JIA in 
standard clinical care.
To obtain figures generalizable on a worldwide basis, the 
involvement of a large number of countries was sought for. 
To reach this goal, participation in the study was first pro-
posed to the national coordinating centre of all countries 
belonging to the Paediatric Rheumatology International Tri-
als Organisation (PRINTO at http://www.print o.it), and at 
least to one qualified paediatric rheumatology centre in the 
US and Canada. For the purposes of this study, the JAMAR 
needed to be translated and cross-culturally adapted and val-
idated in the national language of each participating country 
as per international guidelines.
PRINTO supported the EPOCA project by fostering the 
active involvement of its worldwide membership. PRINTO 
is a non-governmental international network founded by 
Alberto Martini and Nicolino Ruperto in 1996 and based at 
the Istituto Giannina Gaslini of Genoa Italy. The PRINTO 
main goal is to foster, facilitate and co-ordinate the devel-
opment, conduct, analysis, and reporting of multi-centre, 
international clinical trials and/or outcome standardization 
studies in children with rheumatic diseases. PRINTO is 
composed of four main structures: the Advisory Council 
(which acts as the steering committee), the international 
coordinating centre located in Genoa, Italy (which coordi-
nates the international projects), one national coordinator 
for each country (who coordinates the work among the indi-
vidual paediatric rheumatology centres in his/her country 
and was in charge of the national implementation of the 
EPOCA project), and more than 600 centres (hospitals and/
or universities) distributed in 88 countries around the world. 
As of today, PRINTO has collected, for academic studies, 
data of over 37,500 children in 300 centres in 67 countries, 
and, in collaboration with the Paediatric Rheumatology 
Collaborative Study Group (PRCSG at http://www.prcsg 
.org) and pharmaceutical companies, over 3500 children 
for clinical trials in more than 250 centres in 40 countries 
worldwide.
This supplement represents one of the main results of 
this cooperation among the different centres and countries 
belonging to PRINTO. Its objective is to make available 
to the paediatric rheumatology community a standardized 
tool aimed to foster a multidimensional approach in outcome 
assessment of JIA.
The supplement begins with an introductive review article 
that summarizes the study methodology and the sample of 
JIA patients and healthy controls collected for the study. It 
is followed by one article for each of the 49 countries. Each 
paper presents the results of the cross-cultural adaptation 
and psychometric evaluation of the JAMAR in that particu-
lar country, plus a table which compares the demographic, 
disability, physical and psychological data of JIA patients 
and their healthy peers. The EPOCA effort involved the par-
ticipation of more than 300 clinical researchers from 125 
centres in 52 countries.
The cross-cultural adaptation and validation of the 
JAMAR could not be accomplished without the support of 
PRINTO and the cooperation of its members in their local 
paediatric rheumatology centres as well as of the families of 
the JIA patients and healthy controls. This effort led to the 
involvement of more than 10,000 children all over the world.
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